RobotDreams key facts
as of Oct 2026- Developer of artificial intelligence (AI)-based diagnostic software designed for the analysis of hematological data to identify physiological conditions in clinical settings.
- RobotDreams is valued at approximately $11.3M as of Oct 2026 (last reported valuation).
- It has raised $3.3M; the latest was Angel (individual) ($590K) in Feb 2026.
- Notable investors include Plug and Play Tech Center, STARTPLATZ, Austria Wirtschaftsservice, AXOLOTL (Germany), Scale-up Champions — 7 tracked in total.
- Status: Privately Held (backing).
RobotDreams's last reported valuation, Feb 2026. Nothing priced has surfaced since.
- ·Watch RobotDreams: the Monday email on marks, rounds and moves
RobotDreams funding rounds
No funding rounds for RobotDreams are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
RobotDreams valuation
RobotDreams's last reported valuation was $11.3 million in Feb 2026. No priced round, secondary trade or fund mark has surfaced since.
RobotDreams investors
7 investors are on record for RobotDreams, including Plug and Play Tech Center, STARTPLATZ, Austria Wirtschaftsservice and AXOLOTL (Germany).
About RobotDreams
Developer of artificial intelligence (AI)-based diagnostic software designed for the analysis of hematological data to identify physiological conditions in clinical settings. The company's platform utilizes modular, deep learning-powered models that process blood samples without requiring electrocardiogram (ECG) or cardiac biomarker data, enabling healthcare providers to accelerate risk assessment, improve diagnostic accuracy, reduce unnecessary hospital admissions, and detect acute cardiovascular conditions, such as heart attacks, using only the first available blood sample.
- Sector
- Healthcare
- HQ
- Graz, Austria
- Founded
- 2019
- Employees
- 8
- Website
- robotdreams.co/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.